Related Experiment Video
Updated: May 6, 2026

Packaging HIV- or FIV-based Lentivector Expression Constructs & Transduction of VSV-G Pseudotyped Viral Particles
Published on: April 8, 2012
General considerations on the biosafety of virus-derived vectors used in gene therapy and vaccination
Aline Baldo, Eric van den Akker, Hans E Bergmans
1Scientific Institute of Public Health (WIV-ISP), Biosafety and Biotechnology Unit, Rue J. Wytsmanstraat 14, B-1050 Brussels, Belgium. aline.baldo@wiv-isp.be.
Abstract:
This introductory paper gathers general considerations on the biosafety of virus-derived vectors that are used in human gene therapy and/or vaccination. The importance to assess the potential risks for human health and the environment related to the use of genetically modified organisms (GMO) in this case genetically modified viral vectors is highlighted by several examples. This environmental risk assessment is one of the requirements within the European regulatory framework covering the conduct of clinical trials using GMO. Risk assessment methodologies for the environmental risk assessment of genetically modified virus-derived vectors have been developed.
More Related Videos
07:43Author Spotlight: Addressing Regulatory Gaps in Molecular Studies by Quantifying Viral Vectors in Complex Matrices
Published on: July 14, 2023
16:04A Tetracycline-regulated Cell Line Produces High-titer Lentiviral Vectors that Specifically Target Dendritic Cells
Published on: June 19, 2013
Related Concept Videos
Microorganisms in Medicine and Therapeutics
Gene Therapy